BDX·Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology firm focused on improving healthcare outcomes through innovative products and services across its Medical, Connected Care, BioPharma Systems, and Interventional and Life Sciences segments. Operating within the medical instruments and supplies industry, BDX provides a wide array of medical supplies, devices, and diagnostic solutions. In its recent earnings performance, BDX has shown a mixed pattern of beating and missing analyst estimates. For Q1 2026, actual EPS of $2.91 missed the estimate of $3.31, while revenue of $5.25 billion was below the estimate of $5.53 billion. However, in Q2 2026, actual EPS of $2.90 beat the estimate of $2.77, and revenue of $4.71 billion was in line with the estimate of $4.72 billion. Looking at the prior year, Q3 2025 EPS of $3.96 surpassed the estimate of $3.91, and revenue of $5.89 billion exceeded the estimate of $5.89 billion. Q2 2025 saw actual EPS of $3.68 beat the estimate of $3.40, with revenue of $5.51 billion exceeding the estimate of $5.51 billion. The company has a history of exceeding revenue estimates in the last four reported quarters, though EPS performance has been more variable. Recent news indicates that BDX reported better-than-expected second-quarter results, with Barclays raising its price target, though the stock saw minimal movement partly due to significant unusual items impacting statutory profit. Jim Cramer remains a proponent of BDX, highlighting its historically low valuation despite recent analyst price target adjustments. Investors will be watching for continued operational strength, the potential for profit growth if one-off expenses do not recur, and any further analyst commentary that might signal a change in outlook.